Although several approaches to targeting gastric CSC are being tested, the inhibition of STAT3 by napabucasin (formerly BBI608, developed by Boston Biomedical, acquired by Sumitomo Dainippon Pharma in 2012), which has shown promise in early phase trials of patients with advanced-stage GC, is currently being evaluated in a phase III trial. The gene discussed is STAT3; the disease is gastric cancer.